Description
Overview
Think of Tesamorelin as a sophisticated messenger that knocks on your pituitary gland’s door and politely asks it to produce more growth hormone. Unlike synthetic growth hormone that floods the system all at once, Tesamorelin works more like a dimmer switch than an on/off button-it encourages your body to release growth hormone in a more natural, pulsatile pattern. This research peptide has attracted significant scientific interest for its ability to target visceral fat (the stubborn fat around internal organs) while potentially supporting brain function and metabolic health.
Important: This product is exclusively for laboratory research and not for human or animal use. Researchers must follow proper handling protocols and safety guidelines.
This product is strictly for research purposes only. Not approved for human or animal use.
Key Characteristics
MOLECULAR PROFILE
- Formula: C221H366N72O67S
- Weight: 5135.9 g/mol
- CAS: 218949-48-5
- Alternative Names: TH9507, Egrifta
PHYSICAL PROPERTIES
- Form: Lyophilized white to off-white powder
- Solubility: Water-soluble
- Endotoxin: <0.25 EU/mL
- Structure: 44 amino acid peptide
How It Works
Tesamorelin operates by mimicking the body’s natural growth hormone-releasing hormone. When introduced in research settings, it binds to specific receptors (GHRHR) in the pituitary gland-imagine it as having the exact key to unlock growth hormone production.
Primary Mechanisms
GHRHR Receptor Binding
Binds to growth hormone-releasing hormone receptors in the pituitary
Growth Hormone Release
Triggers cascade resulting in increased GH secretion
IGF-1 Stimulation
Promotes production of insulin-like growth factor-1 in the liver
Physiological Effects
Pulsatile Release Pattern
Works with body’s natural rhythms for physiological response
Selective Action
Targeted approach avoiding constant hormone flooding
Metabolic Regulation
Influences fat metabolism and insulin sensitivity
Research Findings
Scientific studies have revealed Tesamorelin’s multi-faceted effects on metabolism, body composition, and cognitive function.
Visceral Fat Reduction
Multiple studies have demonstrated Tesamorelin’s remarkable ability to target dangerous abdominal fat:
- 15-20% reduction in visceral adipose tissue over 6 months
- Selective targeting of fat around internal organs
- Valuable tool for metabolic syndrome research
- Maintained effects with continued administration
Metabolic Health Improvements
Scientists have observed significant metabolic benefits in research subjects:
- Enhanced insulin sensitivity markers
- Improved glucose metabolism
- Better cellular response to insulin
- Potential applications in diabetes research
Cognitive Function Support
Emerging research indicates neuroprotective properties and brain health benefits:
- Improvements in mild cognitive impairment subjects
- Enhanced executive function performance
- Potential role in maintaining neuroplasticity
- Growth hormone’s influence on brain health
Body Composition Changes
Research has documented comprehensive improvements in physical parameters:
- Increased lean muscle mass retention
- Enhanced strength and performance metrics
- Relevant for aging and sarcopenia research
- Improved overall body composition ratios
Bone Health Potential
Preliminary data suggests benefits for skeletal health through hormonal pathways:
- Support for bone density maintenance
- Effects mediated through GH and IGF-1
- Interest in osteoporosis research applications
- Further studies needed for confirmation
Potential Side Effects in Research
During clinical research, scientists have documented several potential side effects that must be considered:
Injection Site Reactions
Redness, swelling, or irritation at administration sites
Hypersensitivity
Rare allergic reactions documented in clinical studies
Fluid Retention
Edema, particularly in extremities, observed in some subjects
Neurological Effects
Headaches and dizziness in some research participants
Joint Discomfort
Reports of arthralgia or joint pain in research settings
Gastrointestinal
Digestive disturbances reported in experimental models
Researchers must carefully monitor for these effects and maintain detailed documentation throughout their studies.
IMPORTANT: This product is exclusively for laboratory research purposes and is not approved for human or veterinary use.
References
- Makimura H, et al. “Tesamorelin reduces visceral adipose tissue and liver fat in INSTI-treated persons with HIV.” Open Forum Infect Dis. 2023.
- Stanley TL, et al. “Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat.” AIDS. 2013.
- Samaras K, et al. “Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III trial.” HIV Med. 2023.
- Makimura H, et al. “Metabolic effects of a growth hormone-releasing factor in visceral adiposity.” J Clin Endocrinol Metab. 2018.
- Vilar L, et al. “Growth hormone-releasing hormone analogs and cognitive function.” Pituitary. 2017.
- Clemmons DR. “The relative roles of growth hormone and IGF-1 in metabolic regulation.” Growth Horm IGF Res. 2019.
- Friedman SD, Baker LD, et al. “Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment.” JAMA Neurol. 2013.
- Stanley TL, Grinspoon SK. “Growth hormone-releasing hormone in HIV-associated lipodystrophy: Current evidence and future directions.” Front Endocrinol. 2024.
- Fourman LT, et al. “Effects of tesamorelin on hepatic transcriptomic signatures.” JCI Insight. 2020.
Shipping & Delivery
Related products
